Although it’s unclear when the SAFER Banking Act will get time on the floor, Senate leadership is adamant about tackling it in the near future. With the bill out of committee, there are a number of reasons cannabis industry stakeholders should be excited about this development.
The demand for cannabis in the Lone Star State is strong. With the likelihood of a fully-functioning medical cannabis market coming soon, and the possibility of decriminalization not too far behind, it’s clear that the future of cannabis is bright in Texas.
In this short Q&A, we sit down with Nick Murer, founder of WECO, to discuss the parts of starting a cannabis business that people sometimes forget about: human resources, employee management, insurance, workers comp and more.
The Texas cannabis industry proliferated under the Farm Bill, as farmers flocked to the crop and retailers generated billions of dollars in commerce. Still though, the Texan market remains stymied by antiquated laws and THC limits.
A slew of headlines in the first half of September highlight issues rampant in the cannabis industry that all involve lab testing, from Maine and New York, to California and Oregon.
The state has a very conservative legislature that operates slowly, so cannabis reform is likely to take a long time. Such progress will happen in a uniquely Texan way.
Amid all of the uncertainty, this piece takes a closer look at the historic announcement, analyzing what rescheduling could mean for an industry plagued by the war on drugs, conflicting laws and high taxes.
The European Union’s regulation of CBD is extremely complex. This series of articles illustrates the regulatory disparities found between the United States, the United Kingdom and the EU, while trying to make sense of it all.
In this series, Husch Blackwell attorneys Wang and Salmons discuss what options are out there for cannabis companies in financial trouble. Part 3 continues the review of different state statutes and how state law receiverships vary.
The European Union’s regulation of CBD is extremely complex. This series of articles illustrates the regulatory disparities found between the United States, the United Kingdom and the EU, while trying to make sense of it all.